**5. Conclusions**

To date, hematological malignancies and metastatic solid tumors have caused a prevalence of over 10 million mortalities annually [3–6]. Antitumor immunotherapy *Cancer Immunotherapy and Cytotoxicity: Current Advances and Challenges DOI: http://dx.doi.org/10.5772/intechopen.105184*

has served as a promising and alternative strategy for improving the outcomes of tumor patients as well as reducing the concomitant cytotoxicity. Objectively, there's still a long way to go and a cohort of central issues need to be solved before large-scale application in cancer immunotherapy. Overall, cancer immunotherapy has become a notable and synergistic anti-tumor remedy for a variety of hematopoietic malignancies and locally advanced solid tumors.
